Kymera Therapeutics reported $51.4M of remaining performance obligations at 31 Dec 2024 and up 3% from the previous quarter. That is 1.1 years of trailing revenue already under contract. Book-to-bill last quarter: 1.23.
Net new backlog added in the latest quarter: $1.70M.
Customer prepayments (contract liabilities) cover 26.5% of the backlog.
The latest filed figure is more than 200 days old.
Kymera Therapeutics backlog history
Remaining performance obligations at each quarter end (bars) against trailing twelve-month revenue (line).
Amounts in USD. Source: SEC XBRL filings.
Quarter end
Backlog (RPO)
TTM revenue
Coverage
Customer prepayments
31 Dec 2024
$51.4M
$47.1M
1.1 yrs
$13.6M
30 Sep 2024
$49.7M
n/a
n/a
$20.0M
30 Jun 2024
$49.1M
n/a
n/a
$22.4M
31 Mar 2024
$42.6M
n/a
n/a
$46.4M
Questions
What is Kymera Therapeutics's backlog?
Kymera Therapeutics reported $51.4M of remaining performance obligations at 31 Dec 2024 and up 3% from the previous quarter. That is 1.1 years of trailing revenue already under contract. Book-to-bill last quarter: 1.23.
About these numbers
Remaining performance obligations (RPO) are revenue a company has contracted but not yet recognised, as reported in its SEC filings (XBRL tag RevenueRemainingPerformanceObligation). Coverage = backlog ÷ trailing twelve-month revenue. Book-to-bill = (change in backlog + revenue) ÷ revenue. Conversion = revenue recognised ÷ the backlog at the start of each quarter, summed over four quarters. Counterparty values come from company filings and releases.